284 related articles for article (PubMed ID: 17728092)
1. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
2. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
3. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Tumminello FM; Badalamenti G; Incorvaia L; Fulfaro F; D'Amico C; Leto G
Med Oncol; 2009; 26(1):10-5. PubMed ID: 18461289
[TBL] [Abstract][Full Text] [Related]
5. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
[TBL] [Abstract][Full Text] [Related]
6. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer.
Nishikawa H; Ozaki Y; Nakanishi T; Blomgren K; Tada T; Arakawa A; Suzumori K
Gynecol Oncol; 2004 Mar; 92(3):881-6. PubMed ID: 14984956
[TBL] [Abstract][Full Text] [Related]
7. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.
Miyake H; Hara I; Eto H
Anticancer Res; 2004; 24(4):2573-7. PubMed ID: 15330217
[TBL] [Abstract][Full Text] [Related]
8. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
Kos J; Krasovec M; Cimerman N; Nielsen HJ; Christensen IJ; Brünner N
Clin Cancer Res; 2000 Feb; 6(2):505-11. PubMed ID: 10690531
[TBL] [Abstract][Full Text] [Related]
9. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ
Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358
[TBL] [Abstract][Full Text] [Related]
10. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
Mountzios G; Terpos E; Syrigos K; Papadimitriou C; Papadopoulos G; Bamias A; Mavrikakis M; Dimopoulos MA
Transl Res; 2010 May; 155(5):247-55. PubMed ID: 20403580
[TBL] [Abstract][Full Text] [Related]
11. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
13. Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath.
Hansen T; Petrow PK; Gaumann A; Keyszer GM; Otto M; Kirkpatrick CJ; Kriegsmann J
Mod Pathol; 2001 Apr; 14(4):318-24. PubMed ID: 11301348
[TBL] [Abstract][Full Text] [Related]
14. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
15. Serum cystatin C in patients with head and neck carcinoma.
Strojan P; Svetic B; Smid L; Kos J
Clin Chim Acta; 2004 Jun; 344(1-2):155-61. PubMed ID: 15149884
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
[TBL] [Abstract][Full Text] [Related]
19. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.
Samouilidou EC; Grapsa E
Ren Fail; 2008; 30(7):711-5. PubMed ID: 18704820
[TBL] [Abstract][Full Text] [Related]
20. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]